Contribution: Industrial Research Assistance Program – Contributions to Firms
Pramana Pharmaceuticals Inc.
$136,500.00
Lead Optimization Studies-Phase II
FY 2020-21 · 2020-07-01
Summary
A lead optimization study to define a clinical candidate amongst a novel series of GPR119 agonists for the treatment of Type2 Diabetes and co-morbidities. This study has the potential to lead to the development of a first in class therapeutic for T2DM and obesity and advancement of a novel therapeutic pipeline to address co-morbidities associated with GPR119 dysregulation including NASH.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
801099599
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2020-07-01 | 2020-21 | $115,000.00 |
| 2 | 2020-07-01 | 2020-21 | $115,000.00 |
| 3 | 2020-07-01 | 2020-21 | $136,500.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 21,500 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 21 500 dollars.
Agreement End Date
2021-03-31
Agreement Number
953841
Agreement Start Date
2020-07-01
Agreement Title
Lead Optimization Studies-Phase II
Agreement Title (French)
Études de référence sur l'optimisation - Phase II
Agreement Type
Contribution
Agreement Value
$136,500.00
Amendment Date
2021-02-17
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
A lead optimization study to define a clinical candidate amongst a novel series of GPR119 agonists for the treatment of Type2 Diabetes and co-morbidities. This study has the potential to lead to the development of a first in class therapeutic for T2DM and obesity and advancement of a novel therapeutic pipeline to address co-morbidities associated with GPR119 dysregulation including NASH.
Description (French)
Une étude de référence sur l'optimisation pour définir un candidat clinique parmi une nouvelle série d'agonistes de GPR119 pour le traitement du diabète de type 2 et des comorbidités. Cette étude a le potentiel de mener au développement d'une thérapie de premier ordre pour le DT2 et l'obésité et à l'avancement d'un nouveau programme thérapeutique pour traiter les comorbidités associées à la dérégulation de GPR119, y compris la SHNA.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Centre
Federal Riding (French)
Vancouver-Centre
Federal Riding Number
59034
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
801099599
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Pramana Pharmaceuticals Inc.
Recipient Postal Code
V6C 3P1
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q2-953841
